Pub Date : 2024-09-01Epub Date: 2024-05-15DOI: 10.1097/INF.0000000000004389
Endi Lanza Galvão, Kathiaja Miranda Souza, Marina Gonçalves de Freitas, Marina Rocha Fonseca Souza, Moisés Willian Aparecido Gonçalves, Gláucia Cota, Sarah Nascimento Silva
Background: Proper treatment for brucellosis is crucial to eradicate the infection and prevent complications, but there is a notable gap in evidence for pediatric treatment. This study aims to address this gap by reviewing current literature, analyzing the efficacy and safety of brucellosis treatment in children, and identifying areas that require further investigation.
Methods: A systematic review, following preferred reporting items for systematic reviews and meta-analyses and Cochrane Handbook guidelines, assessed antimicrobial regimens' efficacy and safety for treating human brucellosis in children. Original human studies with clinical outcomes after drug therapy intervention for children up to 10 years were included. Searches were conducted in Medline, Embase, Cochrane Library and LILACS databases for studies indexed until March 6, 2023. Study selection, data extraction, and bias risk assessment were performed by pairs of reviewers. The quality assessment used Joanna Briggs Institute tools and grading of recommendations assessment, development and evaluation system. Data were analyzed using R software.
Results: A total of 1773 records were reviewed, yielding 11 eligible studies encompassing 1156 children. All included studies presented an observational design. The most reported treatment approaches included sulfamethoxazole-trimethoprim with rifampicin or aminoglycosides, with summarized failure rates of 2% (95% confidence interval: 0.0-0.49) and 13% (95% confidence interval: 0.06-0.29), respectively (very low certainty of evidence). Adverse events and time to defervescence were not reported.
Conclusions: Sulfamethoxazole-trimethoprim + rifampicin were the most prescribed antibiotics for brucellosis for pediatrics. The study highlights the need for more research with robust designs, and emphasizes uncertainty regarding the efficacy of antimicrobial regimens, emphasizing the importance of further investigations to guide specific treatment protocols for this population.
{"title":"Treatment of Childhood Brucellosis: A Systematic Review.","authors":"Endi Lanza Galvão, Kathiaja Miranda Souza, Marina Gonçalves de Freitas, Marina Rocha Fonseca Souza, Moisés Willian Aparecido Gonçalves, Gláucia Cota, Sarah Nascimento Silva","doi":"10.1097/INF.0000000000004389","DOIUrl":"10.1097/INF.0000000000004389","url":null,"abstract":"<p><strong>Background: </strong>Proper treatment for brucellosis is crucial to eradicate the infection and prevent complications, but there is a notable gap in evidence for pediatric treatment. This study aims to address this gap by reviewing current literature, analyzing the efficacy and safety of brucellosis treatment in children, and identifying areas that require further investigation.</p><p><strong>Methods: </strong>A systematic review, following preferred reporting items for systematic reviews and meta-analyses and Cochrane Handbook guidelines, assessed antimicrobial regimens' efficacy and safety for treating human brucellosis in children. Original human studies with clinical outcomes after drug therapy intervention for children up to 10 years were included. Searches were conducted in Medline, Embase, Cochrane Library and LILACS databases for studies indexed until March 6, 2023. Study selection, data extraction, and bias risk assessment were performed by pairs of reviewers. The quality assessment used Joanna Briggs Institute tools and grading of recommendations assessment, development and evaluation system. Data were analyzed using R software.</p><p><strong>Results: </strong>A total of 1773 records were reviewed, yielding 11 eligible studies encompassing 1156 children. All included studies presented an observational design. The most reported treatment approaches included sulfamethoxazole-trimethoprim with rifampicin or aminoglycosides, with summarized failure rates of 2% (95% confidence interval: 0.0-0.49) and 13% (95% confidence interval: 0.06-0.29), respectively (very low certainty of evidence). Adverse events and time to defervescence were not reported.</p><p><strong>Conclusions: </strong>Sulfamethoxazole-trimethoprim + rifampicin were the most prescribed antibiotics for brucellosis for pediatrics. The study highlights the need for more research with robust designs, and emphasizes uncertainty regarding the efficacy of antimicrobial regimens, emphasizing the importance of further investigations to guide specific treatment protocols for this population.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is d -dimer a Useful Diagnostic Tool for Identifying Multisystem Inflammatory Syndrome in Children in Critically Unwell Children?","authors":"Amedine Duret, Harsita Patel, Lakshmi Lakkineni, Robindra Basu Roy, Rebecca Mitting, Elizabeth Whittaker","doi":"10.1097/INF.0000000000004411","DOIUrl":"10.1097/INF.0000000000004411","url":null,"abstract":"","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-06-25DOI: 10.1097/INF.0000000000004431
Nidhin Das K, Vidhu Sharma, Jyoti Shakrawal, Sarbesh Tiwari, Kapil Soni, Bikram Choudhury, Amit Goyal
Background: Invasive fungal sinusitis, particularly mucormycosis, presents a significant clinical challenge, especially in pediatric populations. This retrospective epidemiologic study aimed to investigate the clinical characteristics, risk factors and outcomes associated with this rare but severe condition, with a focus on orbital morbidity.
Methods: Clinical data of 12 pediatric patients diagnosed with invasive fungal sinusitis between 2021 and 2023 were retrospectively analyzed. Diagnosis involved microbiological and histopathologic examinations, alongside radiologic imaging. Treatment comprised surgical intervention and antifungal therapy, with a detailed evaluation of orbital involvement. Statistical analysis included descriptive statistics and logistic regression.
Results: Predominantly affecting males, the median age of the patients was 8 years. Common symptoms included orbital swelling and impaired vision. Imaging revealed characteristic features of invasive fungal sinusitis, including fat stranding and bone erosions. Orbital involvement was extensive, with poor visual outcomes observed in several cases. Surgical debridement and antifungal therapy, including transcutaneous retrobulbar Amphotericin B, were administered. Risk factors associated with poor orbital outcomes included duration of diabetes and glycated hemoglobin levels. Mortality rate stood at 22.2%.
Conclusions: Early diagnosis, aggressive surgical intervention and combined antifungal therapy are essential for improving outcomes. Timely intervention showed stabilization of the orbital disease and better outcomes in pediatric patients. Further research with larger sample sizes is warranted to better understand and address this serious condition.
{"title":"Invasive Fungal Sinusitis and Its Orbital Morbidity in Pediatric Population: A Strategic Treatment Algorithm and Outcomes.","authors":"Nidhin Das K, Vidhu Sharma, Jyoti Shakrawal, Sarbesh Tiwari, Kapil Soni, Bikram Choudhury, Amit Goyal","doi":"10.1097/INF.0000000000004431","DOIUrl":"10.1097/INF.0000000000004431","url":null,"abstract":"<p><strong>Background: </strong>Invasive fungal sinusitis, particularly mucormycosis, presents a significant clinical challenge, especially in pediatric populations. This retrospective epidemiologic study aimed to investigate the clinical characteristics, risk factors and outcomes associated with this rare but severe condition, with a focus on orbital morbidity.</p><p><strong>Methods: </strong>Clinical data of 12 pediatric patients diagnosed with invasive fungal sinusitis between 2021 and 2023 were retrospectively analyzed. Diagnosis involved microbiological and histopathologic examinations, alongside radiologic imaging. Treatment comprised surgical intervention and antifungal therapy, with a detailed evaluation of orbital involvement. Statistical analysis included descriptive statistics and logistic regression.</p><p><strong>Results: </strong>Predominantly affecting males, the median age of the patients was 8 years. Common symptoms included orbital swelling and impaired vision. Imaging revealed characteristic features of invasive fungal sinusitis, including fat stranding and bone erosions. Orbital involvement was extensive, with poor visual outcomes observed in several cases. Surgical debridement and antifungal therapy, including transcutaneous retrobulbar Amphotericin B, were administered. Risk factors associated with poor orbital outcomes included duration of diabetes and glycated hemoglobin levels. Mortality rate stood at 22.2%.</p><p><strong>Conclusions: </strong>Early diagnosis, aggressive surgical intervention and combined antifungal therapy are essential for improving outcomes. Timely intervention showed stabilization of the orbital disease and better outcomes in pediatric patients. Further research with larger sample sizes is warranted to better understand and address this serious condition.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-06-03DOI: 10.1097/INF.0000000000004407
Hing C Kok, Gabrielle B McCallum, Stephanie T Yerkovich, Keith Grimwood, Siew M Fong, Anna M Nathan, Catherine A Byrnes, Robert S Ware, Nachal Nachiappan, Noorazlina Saari, Peter S Morris, Tsin W Yeo, Victor M Oguoma, I Brent Masters, Jessie A de Bruyne, Kah P Eg, Bilawara Lee, Mong H Ooi, John W Upham, Paul J Torzillo, Anne B Chang
Background: Pediatric community-acquired pneumonia (CAP) can lead to long-term respiratory sequelae, including bronchiectasis. We determined if an extended (13-14 days) versus standard (5-6 days) antibiotic course improves long-term outcomes in children hospitalized with CAP from populations at high risk of chronic respiratory disease.
Methods: We undertook a multicenter, double-blind, superiority, randomized controlled trial involving 7 Australian, New Zealand, and Malaysian hospitals. Children aged 3 months to ≤5 years hospitalized with radiographic-confirmed CAP who received 1-3 days of intravenous antibiotics, then 3 days of oral amoxicillin-clavulanate, were randomized to either extended-course (8-day oral amoxicillin-clavulanate) or standard-course (8-day oral placebo) arms. Children were reviewed at 12 and 24 months. The primary outcome was children with the composite endpoint of chronic respiratory symptoms/signs (chronic cough at 12 and 24 months; ≥1 subsequent hospitalized acute lower respiratory infection by 24 months; or persistent and/or new chest radiographic signs at 12-months) at 24-months postdischarge, analyzed by intention-to-treat, where children with incomplete follow-up were assumed to have chronic respiratory symptoms/signs ("worst-case" scenario).
Results: A total of 324 children were randomized [extended-course (n = 163), standard-course (n = 161)]. For our primary outcome, chronic respiratory symptoms/signs occurred in 97/163 (60%) and 94/161 (58%) children in the extended-courses and standard-courses, respectively [relative risk (RR) = 1.02, 95% confidence interval (CI): 0.85-1.22]. Among children where all sub-composite outcomes were known, chronic respiratory symptoms/signs between groups, RR = 1.10, 95% CI: 0.69-1.76 [extended-course = 27/93 (29%) and standard-course = 24/91 (26%)]. Additional sensitivity analyses also revealed no between-group differences.
Conclusion: Among children from high-risk populations hospitalized with CAP, 13-14 days of antibiotics (versus 5-6 days), did not improve long-term respiratory outcomes.
{"title":"Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial.","authors":"Hing C Kok, Gabrielle B McCallum, Stephanie T Yerkovich, Keith Grimwood, Siew M Fong, Anna M Nathan, Catherine A Byrnes, Robert S Ware, Nachal Nachiappan, Noorazlina Saari, Peter S Morris, Tsin W Yeo, Victor M Oguoma, I Brent Masters, Jessie A de Bruyne, Kah P Eg, Bilawara Lee, Mong H Ooi, John W Upham, Paul J Torzillo, Anne B Chang","doi":"10.1097/INF.0000000000004407","DOIUrl":"10.1097/INF.0000000000004407","url":null,"abstract":"<p><strong>Background: </strong>Pediatric community-acquired pneumonia (CAP) can lead to long-term respiratory sequelae, including bronchiectasis. We determined if an extended (13-14 days) versus standard (5-6 days) antibiotic course improves long-term outcomes in children hospitalized with CAP from populations at high risk of chronic respiratory disease.</p><p><strong>Methods: </strong>We undertook a multicenter, double-blind, superiority, randomized controlled trial involving 7 Australian, New Zealand, and Malaysian hospitals. Children aged 3 months to ≤5 years hospitalized with radiographic-confirmed CAP who received 1-3 days of intravenous antibiotics, then 3 days of oral amoxicillin-clavulanate, were randomized to either extended-course (8-day oral amoxicillin-clavulanate) or standard-course (8-day oral placebo) arms. Children were reviewed at 12 and 24 months. The primary outcome was children with the composite endpoint of chronic respiratory symptoms/signs (chronic cough at 12 and 24 months; ≥1 subsequent hospitalized acute lower respiratory infection by 24 months; or persistent and/or new chest radiographic signs at 12-months) at 24-months postdischarge, analyzed by intention-to-treat, where children with incomplete follow-up were assumed to have chronic respiratory symptoms/signs (\"worst-case\" scenario).</p><p><strong>Results: </strong>A total of 324 children were randomized [extended-course (n = 163), standard-course (n = 161)]. For our primary outcome, chronic respiratory symptoms/signs occurred in 97/163 (60%) and 94/161 (58%) children in the extended-courses and standard-courses, respectively [relative risk (RR) = 1.02, 95% confidence interval (CI): 0.85-1.22]. Among children where all sub-composite outcomes were known, chronic respiratory symptoms/signs between groups, RR = 1.10, 95% CI: 0.69-1.76 [extended-course = 27/93 (29%) and standard-course = 24/91 (26%)]. Additional sensitivity analyses also revealed no between-group differences.</p><p><strong>Conclusion: </strong>Among children from high-risk populations hospitalized with CAP, 13-14 days of antibiotics (versus 5-6 days), did not improve long-term respiratory outcomes.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141237728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-07-26DOI: 10.1097/INF.0000000000004409
Deepika Kainth, Satya Prakash, M Jeeva Sankar
Background: Timely diagnosis of neonatal sepsis is challenging. We aimed to systematically evaluate the diagnostic performance of sophisticated machine learning (ML) techniques for the prediction of neonatal sepsis.
Methods: We searched MEDLINE, Embase, Web of Science and Cochrane CENTRAL databases using "neonate," "sepsis" and "machine learning" as search terms. We included studies that developed or validated an ML algorithm to predict neonatal sepsis. Those incorporating automated vital-sign data were excluded. Among 5008 records, 74 full-text articles were screened. Two reviewers extracted information as per the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) checklist. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guideline extension for diagnostic test accuracy reviews and used the PROBAST tool for risk of bias assessment. Primary outcome was a predictive performance of ML models in terms of sensitivity, specificity and positive and negative predictive values. We generated a hierarchical summary receiver operating characteristics curve for pooled analysis.
Results: Of 19 studies (15,984 participants) with 76 ML models, the random forest algorithm was the most employed. The candidate predictors per model ranged from 5 to 93; most included birth weight and gestation. None performed external validation. The risk of bias was high (18 studies). For the prediction of any sepsis (14 studies), pooled sensitivity was 0.87 (95% credible interval: 0.75-0.94) and specificity was 0.89 (95% credible interval: 0.77-0.95). Pooled area under the receiver operating characteristics curve was 0.94 (95% credible interval: 0.92-0.96). All studies, except one, used data from high- or upper-middle-income countries. With unavailable probability thresholds, the performance could not be assessed with sufficient precision.
Conclusions: ML techniques have good diagnostic accuracy for neonatal sepsis. The need for the development of context-specific models from high-burden countries is highlighted.
{"title":"Diagnostic Performance of Machine Learning-based Models in Neonatal Sepsis: A Systematic Review.","authors":"Deepika Kainth, Satya Prakash, M Jeeva Sankar","doi":"10.1097/INF.0000000000004409","DOIUrl":"10.1097/INF.0000000000004409","url":null,"abstract":"<p><strong>Background: </strong>Timely diagnosis of neonatal sepsis is challenging. We aimed to systematically evaluate the diagnostic performance of sophisticated machine learning (ML) techniques for the prediction of neonatal sepsis.</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, Web of Science and Cochrane CENTRAL databases using \"neonate,\" \"sepsis\" and \"machine learning\" as search terms. We included studies that developed or validated an ML algorithm to predict neonatal sepsis. Those incorporating automated vital-sign data were excluded. Among 5008 records, 74 full-text articles were screened. Two reviewers extracted information as per the CHARMS (CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies) checklist. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guideline extension for diagnostic test accuracy reviews and used the PROBAST tool for risk of bias assessment. Primary outcome was a predictive performance of ML models in terms of sensitivity, specificity and positive and negative predictive values. We generated a hierarchical summary receiver operating characteristics curve for pooled analysis.</p><p><strong>Results: </strong>Of 19 studies (15,984 participants) with 76 ML models, the random forest algorithm was the most employed. The candidate predictors per model ranged from 5 to 93; most included birth weight and gestation. None performed external validation. The risk of bias was high (18 studies). For the prediction of any sepsis (14 studies), pooled sensitivity was 0.87 (95% credible interval: 0.75-0.94) and specificity was 0.89 (95% credible interval: 0.77-0.95). Pooled area under the receiver operating characteristics curve was 0.94 (95% credible interval: 0.92-0.96). All studies, except one, used data from high- or upper-middle-income countries. With unavailable probability thresholds, the performance could not be assessed with sufficient precision.</p><p><strong>Conclusions: </strong>ML techniques have good diagnostic accuracy for neonatal sepsis. The need for the development of context-specific models from high-burden countries is highlighted.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-05-07DOI: 10.1097/INF.0000000000004375
Côme Horvat, Cécile Chauvel, Jean-Sebastien Casalegno, Mehdi Benchaib, Dominique Ploin, Marta C Nunes
Background: Respiratory syncytial virus (RSV) poses a substantial threat to infants, often leading to challenges in hospital capacity. With recent pharmaceutical developments to be used during the prenatal and perinatal periods aimed at decreasing the RSV burden, there is a pressing need to identify infants at risk of severe disease. We aimed to stratify the risk of developing a clinically severe RSV infection in infants under 1 year of age.
Methods: This retrospective observational study was conducted at the Hospices Civils de Lyon, France, involving infants born between 2014 and 2018. This study focused on infants hospitalized with severe and very severe acute lower respiratory tract infections associated with RSV (SARI-WI group). Data collection included perinatal information and clinical data, with machine-learning algorithms used to discriminate SARI-WI cases from nonhospitalized infants.
Results: Of 42,069 infants, 555 developed SARI-WI. Infants born in November were very likely (>80%) predicted SARI-WI. Infants born in October were very likely predicted SARI-WI except for births at term by vaginal delivery and without siblings. Infants were very unlikely (<10%) predicted SARI-WI when all the following conditions were met: born in other months, at term, by vaginal delivery and without siblings. Other infants were possibly (10-30%) or probably (30-80%) predicted SARI-WI.
Conclusions: Although RSV preventive measures are vital for all infants, and specific recommendations exist for patients with high-risk comorbidities, in situations where prioritization becomes necessary, infants born just before or within the early weeks of the epidemic should be considered as a risk group.
{"title":"RSV Severe Infection Risk Stratification in a French 5-Year Birth Cohort Using Machine-learning.","authors":"Côme Horvat, Cécile Chauvel, Jean-Sebastien Casalegno, Mehdi Benchaib, Dominique Ploin, Marta C Nunes","doi":"10.1097/INF.0000000000004375","DOIUrl":"10.1097/INF.0000000000004375","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) poses a substantial threat to infants, often leading to challenges in hospital capacity. With recent pharmaceutical developments to be used during the prenatal and perinatal periods aimed at decreasing the RSV burden, there is a pressing need to identify infants at risk of severe disease. We aimed to stratify the risk of developing a clinically severe RSV infection in infants under 1 year of age.</p><p><strong>Methods: </strong>This retrospective observational study was conducted at the Hospices Civils de Lyon, France, involving infants born between 2014 and 2018. This study focused on infants hospitalized with severe and very severe acute lower respiratory tract infections associated with RSV (SARI-WI group). Data collection included perinatal information and clinical data, with machine-learning algorithms used to discriminate SARI-WI cases from nonhospitalized infants.</p><p><strong>Results: </strong>Of 42,069 infants, 555 developed SARI-WI. Infants born in November were very likely (>80%) predicted SARI-WI. Infants born in October were very likely predicted SARI-WI except for births at term by vaginal delivery and without siblings. Infants were very unlikely (<10%) predicted SARI-WI when all the following conditions were met: born in other months, at term, by vaginal delivery and without siblings. Other infants were possibly (10-30%) or probably (30-80%) predicted SARI-WI.</p><p><strong>Conclusions: </strong>Although RSV preventive measures are vital for all infants, and specific recommendations exist for patients with high-risk comorbidities, in situations where prioritization becomes necessary, infants born just before or within the early weeks of the epidemic should be considered as a risk group.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11319071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01Epub Date: 2024-05-16DOI: 10.1097/INF.0000000000004400
Milena Demey, Arnaud Bruyneel, Olga Chatzis, Christelle Christiaens, Veerle Cossey, Gabrielle De Crombrugghe, Lieve De Lille, Tessa Goetghebuer, Emmanuelle Gueulette, Marc Hainaut, Catherine Heijmans, Hortense Hubinont, Phu-Quoc Lé, Laurie Lecomte, Inge Mattijs, Céline Mignon, Bénédicte Mondovits, Marine Rodesch, Shancy Rooze, Petra Schelstraete, Diane Stroobant, Laurence Thielemans, Ingrid Thomas, Selimaj K Valbona, Emmi Van Damme, Dimitri Van der Linden, Jens Van Praet, Françoise Vermeulen, David Weynants, Anne Tilmanne
Our study aimed to assess the severity of severe acute respiratory syndrome coronavirus 2 infection in hospitalized infants under 40 days old, across 21 Belgian hospitals between 2020 and 2022. Of the 365 infants studied, 14.2% needed respiratory support. The median hospital stay was 3 days (interquartile range, 2-4), and there were no deaths. Infection severity was similar during the Omicron and Alpha/Delta periods.
{"title":"SARS-CoV-2 Infection in Children Less Than Forty Days Hospitalized in Belgium Between 2020 and 2022.","authors":"Milena Demey, Arnaud Bruyneel, Olga Chatzis, Christelle Christiaens, Veerle Cossey, Gabrielle De Crombrugghe, Lieve De Lille, Tessa Goetghebuer, Emmanuelle Gueulette, Marc Hainaut, Catherine Heijmans, Hortense Hubinont, Phu-Quoc Lé, Laurie Lecomte, Inge Mattijs, Céline Mignon, Bénédicte Mondovits, Marine Rodesch, Shancy Rooze, Petra Schelstraete, Diane Stroobant, Laurence Thielemans, Ingrid Thomas, Selimaj K Valbona, Emmi Van Damme, Dimitri Van der Linden, Jens Van Praet, Françoise Vermeulen, David Weynants, Anne Tilmanne","doi":"10.1097/INF.0000000000004400","DOIUrl":"10.1097/INF.0000000000004400","url":null,"abstract":"<p><p>Our study aimed to assess the severity of severe acute respiratory syndrome coronavirus 2 infection in hospitalized infants under 40 days old, across 21 Belgian hospitals between 2020 and 2022. Of the 365 infants studied, 14.2% needed respiratory support. The median hospital stay was 3 days (interquartile range, 2-4), and there were no deaths. Infection severity was similar during the Omicron and Alpha/Delta periods.</p>","PeriodicalId":19858,"journal":{"name":"Pediatric Infectious Disease Journal","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}